Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telmisartan + indapamide is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of hypertension (high blood pressure). Telmisartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to its type 1 receptor in vascular smooth muscle and the adrenal gland, resulting in vasodilation and reduced blood pressure. Indapamide is a thiazide-like diuretic that acts at the distal tubule in the kidney to promote excretion of sodium and water, while also exerting direct vasodilatory effects on blood vessels. The combination effectively lowers blood pressure, reduces cardiovascular risk, and may decrease the risk of stroke, heart attack, and edema. This therapy is indicated as first-line or adjunctive treatment for adults with hypertension[1][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telmisartan + indapamide.